Immune checkpoint inhibitor therapy (ICT) targeting PD-1/PD-L1 or CTLA-4 has revolutionized cancer treatment, yielding durable remission, and even cures, for select patients with previously incurable cancers (1–5). Here, CTLA4 is linked to cancer.